Prostate Cancer Clinical Trials in Nashville

Showing 221-240 of 359 trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

NCT03205176

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

Malignant Solid TumorsLymphomaOvarian Cancer+3 more

AstraZeneca49 participantsStarted Jun 2017

Sarasota, Florida, United States • Oklahoma City, Oklahoma, United States • Nashville, Tennessee, United States +1 more locations

COMPLETEDPhase 3< 1 mile

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy given at the same time as hormone therapy is more effective than chemotherapy given after hormone therapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy given at the same time as hormone therapy with that of chemotherapy given after hormone therapy in treating patients who have prostate cancer.

Prostate Cancer

Radiation Therapy Oncology Group21 participantsStarted Oct 2002

Phoenix, Arizona, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +75 more locations

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Prostate Cancer Trials in Other Cities

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Perioperative Post-Prostatectomy Incontinence Home Telehealth Program

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Other Conditions in Nashville